XML 36 R25.htm IDEA: XBRL DOCUMENT v3.25.3
FAIR VALUE MEASUREMENTS (Tables)
9 Months Ended
Sep. 30, 2025
Fair Value Disclosures [Abstract]  
Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis
The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy:
September 30, 2025December 31, 2024
(in millions)Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets:
Available-for-sale debt securities:
U.S. treasury securities$757 $— $— $757 $— $— $— $— 
U.S. government agencies securities— — — — — — 
Corporate debt securities— 963 — 963 — — — — 
Residential mortgage and asset-backed securities— 300 — 300 — — — — 
Equity securities:
Money market funds5,745 — — 5,745 8,502 — — 8,502 
Publicly traded equity securities(1)
1,804 — — 1,804 1,561 — — 1,561 
Deferred compensation plan401 — — 401 343 — — 343 
Foreign currency derivative contracts— 31 — 31 — 128 — 128 
Total$8,707 $1,298 $— $10,005 $10,405 $128 $— $10,533 
Liabilities:
Contingent consideration liability$— $— $274 $274 $— $— $206 $206 
Deferred compensation plan401 — — 401 343 — — 343 
Foreign currency derivative contracts— 92 — 92 — — 
Total$401 $92 $274 $767 $343 $$206 $552 
_______________________________
(1)    Publicly traded equity securities include our investment in Galapagos NV (“Galapagos”) of $570 million and Assembly Biosciences, Inc. (“Assembly”) of $115 million as of September 30, 2025, which are subject to contractual sale restrictions. Our investment in Assembly is restricted until October 2025, and our investment in Galapagos is restricted until December 2025. For additional details on Galapagos, see Note 6. Acquisitions, Collaborations and Other Arrangements.
Summary of Change in Fair Value of Contingent Consideration Liability
The following table summarizes the change in fair value of our contingent consideration liability:
Three Months EndedNine Months Ended
September 30,September 30,
(in millions)2025202420252024
Beginning balance$271 $208 $206 $228 
Changes in valuation assumptions(1)
41 (6)
Effect of foreign exchange remeasurement(2)
— 27 
Ending balance(3)
$274 $222 $274 $222 
________________________________
(1)    Included in Research and development expenses on our Condensed Consolidated Statements of Operations. The changes for the nine months ended September 30, 2025 primarily related to changes in assumptions around probability.
(2)    Included in Other (income) expense, net on our Condensed Consolidated Statements of Operations.
(3)    Included in Other current liabilities and Other long-term liabilities on our Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024, respectively.
Summary of Total Estimated Fair Value and Carrying Value of Senior Unsecured Notes
The following table summarizes the total estimated fair value and carrying value of our senior unsecured notes, determined using Level 2 inputs based on their quoted market values:
(in millions)September 30, 2025December 31, 2024
Fair value$22,398 $23,335 
Carrying value$23,823 $25,562